Literature DB >> 9324262

Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins.

X Z Li1, H Nikaido, K E Williams.   

Abstract

Silver-resistant mutants were selected by stepwise exposure of silver-susceptible clinical strains of Escherichia coli, two of which did not contain any plasmids, to either silver nitrate or silver sulfadiazine. These mutants showed complete cross-resistance to both compounds. They showed low-level cross-resistance to cephalosporins and HgCl2 but not to other heavy metals. The Ag-resistant mutants had decreased outer membrane (OM) permeability to cephalosporins, and all five resistant mutants tested were deficient in major porins, either OmpF or OmpF plus OmpC. However, the well-studied OmpF- and/or OmpC-deficient mutants of laboratory strains K-12 and B/r were not resistant to either silver compound. Resistant strains accumulated up to fourfold less (110m)AgNO3 than the parental strains. The treatment of cells with carbonyl cyanide m-chlorophenylhydrazone increased Ag accumulation in Ag-susceptible and -resistant strains, suggesting that even the wild-type Ag-susceptible strains had an endogenous Ag efflux activity, which occurred at higher levels in Ag-resistant mutants. The addition of glucose as an energy source to starved cells activated the efflux of Ag. The results suggest that active efflux, presumably coded by a chromosomal gene(s), may play a major role in silver resistance, which is likely to be enhanced synergistically by decreases in OM permeability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324262      PMCID: PMC179518          DOI: 10.1128/jb.179.19.6127-6132.1997

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  26 in total

1.  Solubility studies of silver sulfadiazine.

Authors:  R U Nesbitt; B J Sandmann
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

Review 2.  Bacterial heavy metal resistance: new surprises.

Authors:  S Silver; L T Phung
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

3.  Pleiotropic transport mutants of Escherichia coli lack porin, a major outer membrane protein.

Authors:  P Bavoil; H Nikaido; K von Meyenburg
Journal:  Mol Gen Genet       Date:  1977-12-14

4.  Role of a major outer membrane protein in Escherichia coli.

Authors:  J F Lutkenhaus
Journal:  J Bacteriol       Date:  1977-08       Impact factor: 3.490

5.  Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin.

Authors:  K J Harder; H Nikaido; M Matsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

6.  Binding of silver sulfadiazine to the cellular components of Pseudomonas aeruginosa.

Authors:  S M Modak; C L Fox
Journal:  Biochem Pharmacol       Date:  1973-10-01       Impact factor: 5.858

7.  Outer membrane proteins of Escherichia coli. VII. Evidence that bacteriophage-directed protein 2 functions as a pore.

Authors:  A P Pugsley; C A Schnaitman
Journal:  J Bacteriol       Date:  1978-03       Impact factor: 3.490

8.  Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli.

Authors:  L McMurry; R E Petrucci; S B Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

9.  Silver-resistant Enterobacteriaceae from hospital patients.

Authors:  A T Hendry; I O Stewart
Journal:  Can J Microbiol       Date:  1979-08       Impact factor: 2.419

10.  Sulfadiazine silver-resistant Pseudomonas in Burns. New topical agents.

Authors:  S M Modak; C L Fox
Journal:  Arch Surg       Date:  1981-07
View more
  68 in total

Review 1.  Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.

Authors:  Peter Gilbert; Andrew J McBain
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Engineered Escherichia coli silver-binding periplasmic protein that promotes silver tolerance.

Authors:  Ruth Hall Sedlak; Marketa Hnilova; Carolynn Grosh; Hanson Fong; Francois Baneyx; Dan Schwartz; Mehmet Sarikaya; Candan Tamerler; Beth Traxler
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

Review 3.  Silver dressings: their role in wound management.

Authors:  David J Leaper
Journal:  Int Wound J       Date:  2006-12       Impact factor: 3.315

4.  Studies on the biocompatibility and the interaction of silver nanoparticles with human mesenchymal stem cells (hMSCs).

Authors:  C Greulich; S Kittler; M Epple; G Muhr; M Köller
Journal:  Langenbecks Arch Surg       Date:  2009-03-12       Impact factor: 3.445

Review 5.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

6.  Evaluating antimicrobial efficacy of new commercially available silver dressings.

Authors:  Marion H Cavanagh; Robert E Burrell; Patricia L Nadworny
Journal:  Int Wound J       Date:  2010-10       Impact factor: 3.315

7.  Porins increase copper susceptibility of Mycobacterium tuberculosis.

Authors:  Alexander Speer; Jennifer L Rowland; Mehri Haeili; Michael Niederweis; Frank Wolschendorf
Journal:  J Bacteriol       Date:  2013-09-06       Impact factor: 3.490

8.  Silver resistance genes are overrepresented among Escherichia coli isolates with CTX-M production.

Authors:  Susanne Sütterlin; Petra Edquist; Linus Sandegren; Marlen Adler; Thomas Tängdén; Mirva Drobni; Björn Olsen; Asa Melhus
Journal:  Appl Environ Microbiol       Date:  2014-08-15       Impact factor: 4.792

9.  Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles.

Authors:  Evan M Hetrick; Jae Ho Shin; Heather S Paul; Mark H Schoenfisch
Journal:  Biomaterials       Date:  2009-02-23       Impact factor: 12.479

Review 10.  Nanofibers offer alternative ways to the treatment of skin infections.

Authors:  T D J Heunis; L M T Dicks
Journal:  J Biomed Biotechnol       Date:  2010-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.